(Reuters) -AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of overall survival in a late-stage trial.
The company was testing the drug in newly-diagnosed patients with higher-risk myelodysplastic syndromes, a group of cancers in which the bone marrow doesn’t produce enough healthy blood cells.
The drug, Venclexta, is already approved for the treatment of another type of blood cancer called leukemia and is jointly developed by AbbVie and Swiss drugmaker Roche.
U.S.-based AbbVie reported global Venclexta sales of about $2.6 billion in 2024.
(Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo)
Comments